Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

161. Work and the Menopause: A Guide for Managers

Work and the Menopause: A Guide for Managers Work and the Menopause: A Guide for Managers Introduction: Older women workers Women comprise approximately half (47 percent) of the UK’s workforce. About 3.5 million are women aged 50 and over. Occupational health issues for older workers in general, and older women workers in particular, have often been ignored. Many of today’s women workers are, or will be, working though a rarely discussed stage of life: the menopause. The British Occupational (...) Health Research Foundation (BOHRF) commissioned researchers at the University of Nottingham, led by Professor Amanda Griffiths, to explore women’s experience of working through the menopause. The research aimed to explore women’s experiences of working through the menopause, and to provide information for employers, for women and for those who advise them. It is based on interviews with women in managerial and administrative roles in several sectors 1 , and on responses to over 900 questionnaires

2010 British Occupational Health Research Foundation

162. Women's Experience of Working through the Menopause

Women's Experience of Working through the Menopause Institute of Work, Health & Organisations http://www.nottingham.ac.uk/iwho Women’s Experience of Working through the Menopause Amanda Griffiths, Sara MacLennan & Yin Yee Vida Wong A Report for The British Occupational Health Research Foundation 2010 2 CONTENTS TERMS OF REFERENCE 4 ACKNOWLEDGEMENTS 4 AUTHORS 5 INSTITUTE OF WORK, HEALTH & ORGANISATIONS 5 1. EXECUTIVE SUMMARY 6 2. INTRODUCTION & BACKGROUND 8 3. OVERVIEW OF RESEARCH DESIGN 9 4 (...) . REVIEW OF PUBLISHED LITERATURE 10 4.1 The menopause and its reported effects on health and well-being 10 4.2 Work and the menopause 11 4.3 Disclosure 12 4.4 Treatments for the menopause 12 4.5 Summary 13 5. INTERVIEW STUDY 14 5.1 Interview design 14 5.2 Data collection 14 5.3 Measurement of menopausal status 14 5.4 Participants 15 5.5 Transcription 15 5.6 Data analysis 15 5.7 Inter-rater reliability 15 5.8 Interview study: Results - Themes 15 5.8.2 Cognitive and emotional response (attributed

2010 British Occupational Health Research Foundation

163. Herbal medicines for menopausal symptoms

Herbal medicines for menopausal symptoms Herbal medicines for menopausal symptoms | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Herbal medicines for menopausal symptoms Article Text Reprinted from DTB Herbal medicines for menopausal symptoms Reprinted from: DTB 2009;47:2–6 Abstract Many women are now using herbal medicines to try to relieve menopausal symptoms such as hot flushes and night sweats, in light of recent evidence suggesting that hormone

2010 Evidence-Based Nursing

164. Women's Health Initiative randomised ontrolled trial: Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause

Women's Health Initiative randomised ontrolled trial: Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause Article Text Therapeutics Women's Health Initiative randomised ontrolled trial Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause S. Mitchell Harman Statistics from Altmetric.com Commentary on: Toh S , Hernández-Díaz S , Logan R

2010 Evidence-Based Medicine (Requires free registration)

165. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis

Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A CRD summary This review concluded that black cohosh may reduce the frequency of vasomotor symptoms associated with menopause and that more studies were warranted on its (...) effectiveness and safety. The authors' conclusions appeared to reflect the evidence, but given the likelihood of biases in identifying relevant studies it was difficult to verify these conclusions. Authors' objectives To investigate the efficacy of preparations containing black cohosh on reduction of vasomotor symptoms associated with menopause. Searching English-language studies were identified through a search of PubMed, EMBASE and The Cochrane Library to January 2008. Search terms were reported

2010 DARE.

166. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy

Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen (...) sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy Josefsson ML, Leinster SJ CRD summary This review concluded that women with oestrogen-sensitive early breast cancer who switched to treatment with aromatase inhibitors after two to three years of tamoxifen had improved overall survival compared to those who stayed on tamoxifen for five years. Sequenced therapy appeared to be the preferred treatment regime. Despite poor reporting

2010 DARE.

167. Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis

Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

168. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause (Full text)

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause The authors further analyzed results from the Women's Health Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without medroxyprogesterone acetate, focusing on health benefits versus risks among women who initiated hormone therapy soon after menopause. Data from the Women's Health Initiative observational study (1993-2004) were included in some analyses for additional (...) precision. Results are presented here for incident coronary heart disease, stroke, venous thromboembolism, breast cancer, colorectal cancer, endometrial cancer, or hip fracture; death from other causes; a summary global index; total cancer; and total mortality. Hazard ratios for breast cancer and total cancer were comparatively higher (P < 0.05) among women who initiated hormone therapy soon after menopause, for both regimens. Among these women, use of conjugated equine estrogens appeared to produce

2009 EvidenceUpdates PubMed

169. Bone health. In: Menopause and osteoporosis update 2009.

Bone health. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

170. Mood, memory, and cognition. In: Menopause and osteoporosis update 2009.

Mood, memory, and cognition. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2009 Society of Obstetricians and Gynaecologists of Canada

171. Urogenital health. In: Menopause and osteoporosis update 2009.

Urogenital health. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

172. Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009.

Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2009 Society of Obstetricians and Gynaecologists of Canada

173. Cardiovascular disease. In: Menopause and osteoporosis update 2009.

Cardiovascular disease. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2009 Society of Obstetricians and Gynaecologists of Canada

174. Vasomotor symptoms. In: Menopause and osteoporosis update 2009.

Vasomotor symptoms. In: Menopause and osteoporosis update 2009. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2009 Society of Obstetricians and Gynaecologists of Canada

175. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety (PubMed)

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety The objective of the study was to assess the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for the treatment of vasomotor symptoms.This was a 26 week, double-blind, placebo-controlled trial of 567 postmenopausal women (mean age, 53.7 years; time since natural menopause, 4.8 years) experiencing 50 or more (...) only.Desvenlafaxine is an effective treatment for menopausal HFs.

2009 EvidenceUpdates

176. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms.

NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2009 National Institutes of Health (NIH) State-of-the-Science Panel

177. Hormone therapy for endometriosis and surgical menopause. (PubMed)

Hormone therapy for endometriosis and surgical menopause. Endometriosis is characterized by the presence of ectopic endometrial tissue that might lead to many distressing and debilitating symptoms. Despite available studies supporting standard hormone therapy for women with endometriosis and post-surgical menopause, there is still a concern that estrogens may induce a recurrence of the disease and its symptoms.This review aimed to look at pain and disease recurrence in women with endometriosis (...) recurrence or exacerbation of endometriosis This outcome was not reported in the first trial. The second found that 2/115 of the treatment group developed recurrence of endometriosis with no recurrence reported in the no-treatment group. This was not statistically significant. No woman was re-operated on in the no-treatment group compared with 2/115 in the treatment group.Hormone replacement therapy for women with endometriosis in post-surgical menopause could result in pain and disease recurrence

2009 Cochrane

178. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin (Full text)

Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin Pearce C L, Chung K, Pike M C, Wu A H CRD summary The authors concluded that oestrogen therapy use increased ovarian cancer in a duration-dependent manner; adding progestins (...) appeared to reduce this effect to some extent. The conclusions appeared to be supported by the evidence but the limited search, lack of reporting of review methods and study quality, and reliance upon predominantly observational studies mean that findings should be interpreted with caution. Authors' objectives To examine the relationship between oestrogen-only and oestrogen plus progestin menopausal hormone therapy and the risk of ovarian cancer. Searching PubMed was searched through to December 2007

2009 DARE. PubMed

179. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis (Full text)

Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis Hooper L, Ryder JJ, Kurzer MS, Lampe JW, Messina (...) reported. One author had links with a manufacturer of soy/isoflavone products. Authors' conclusions Isoflavone-rich soy products decrease follicle stimulating hormone and luteinizing hormone in premenopausal women and may increase oestradiol in post-menopausal women. Clinical implications of these changes are yet to be determined. CRD commentary The review question was clearly stated and inclusion criteria were appropriately defined. Several relevant sources were searched. Some attempts were made

2009 DARE. PubMed

180. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Lekander I, Borgstrom F, Strom O, Zethraeus N, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of hormone replacement therapy (HRT) in women aged 50 years, who had menopausal symptoms, in comparison with no treatment. The authors concluded that HRT for women with menopausal symptoms was cost-effective. The methods were appropriate, but little information on the sources of the clinical and cost data was provided. The issue

2009 NHS Economic Evaluation Database.